Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Increased by Geode Capital Management LLC

Geode Capital Management LLC lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,540,870 shares of the biopharmaceutical company’s stock after acquiring an additional 574,421 shares during the quarter. Geode Capital Management LLC’s holdings in Gilead Sciences were worth $2,302,119,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. FMR LLC grew its stake in shares of Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after buying an additional 14,680,161 shares in the last quarter. Wellington Management Group LLP lifted its stake in Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after acquiring an additional 11,665,593 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in Gilead Sciences by 350.1% in the third quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock worth $193,274,000 after purchasing an additional 1,793,145 shares in the last quarter. International Assets Investment Management LLC raised its holdings in Gilead Sciences by 8,238.4% during the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock valued at $137,708,000 after buying an additional 1,622,806 shares in the last quarter. Finally, Pacer Advisors Inc. lifted its position in shares of Gilead Sciences by 24.7% in the second quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company’s stock worth $541,310,000 after buying an additional 1,564,792 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 476,591 shares of company stock worth $43,747,615 in the last quarter. 0.29% of the stock is owned by corporate insiders.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $90.59 on Tuesday. The firm has a market capitalization of $112.90 billion, a PE ratio of 1,006.56, a price-to-earnings-growth ratio of 2.86 and a beta of 0.18. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The firm has a 50-day moving average price of $89.33 and a 200 day moving average price of $78.89.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.29 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post 4.37 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.40%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

Analysts Set New Price Targets

GILD has been the topic of a number of recent analyst reports. Robert W. Baird raised their price objective on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $74.00 to $96.00 in a research note on Monday, October 21st. Truist Financial raised their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research note on Friday, November 8th. Finally, Citigroup assumed coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $125.00 target price for the company. Twelve equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and four have given a strong buy rating to the company. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $95.41.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.